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In the very near future, all cancer patients coming into the clinics will have their genomic
material profiled, and we will need computational approaches that can make sense out
of these data sets to enable more effective cancer therapies based on a patient’s genomic
profiling results. Here, we will first introduce computational utilities that we have been
developing to facilitate cancer genomics studies. These will include: PiHelper, an open
source framework for drug-target and antibody-target data; cBioPortal, a web-based tool
that provides visualization, analysis and download of large-scale cancer genomics data
sets; and Pathway Commons, a network biology resource that acts as a convenient point
of access to biological pathway information collected from public pathway databases.
We will then give two examples to how these resources can be used in conjunction
with large-scale cancer genomics profiling projects, in particular the Cancer Genome
Atlas (TCGA). First, we will describe our work involving prediction of individualized
therapeutic vulnerabilities in cancer from genomic profiles, where we show that random
passenger genomic events can create patient-specific therapeutic vulnerabilities that can
be exploited by targeted drugs. Second, we will show how comprehensive analysis
of cancer genomics data sets can reveal interesting biological insights about specific
alteration events. In particular, we will describe our computational characterization of
cancer-associated recurrent mutations in RNase III domains of DICER1, again using the
TCGA data set.
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CHAPTER 1
INTRODUCTION: CANCER GENOMICS AND COMPUTATIONAL
APPROACHES IN CANCER RESEARCH
1.1 Cancer genomics
The genome is the genetic material in our cells and is made of deoxyribonucleic acid
(DNA). DNA molecules in our genomes form double-stranded molecules called dou-
ble helices, structures formed by two strands coiling around each other. Human cells
normally have around three billion DNA base pairs that are packed into higher-level
structures called chromosomes. Each human has a total of 23 pairs of chromosomes–
one set coming from the mother, the other from the father.
Cancer is considered as a disease of the genome, where specific changes in the ge-
netic material are the reason why a normal cell becomes cancerous. By sequencing
cancer genomes, we can identify alterations (e.g. structural abnormalities and point mu-
tations) in these cancer cells. This enables characterization of cancer-associated changes
with respect to normal cells for a better understanding of cancer biology. Cancer ge-
nomics is the study of these changes, usually in the context of genes (functional units
on the genome), and how they affect cellular functions that eventually lead to cancer.
1.2 Large-scale cancer genomics projects
Conventional molecular biology approaches play an important role for in-depth charac-
terization of specific cellular entities; but the use of these approaches are not feasible for
global screening of multiple biological entities and their functional roles in cancer. Due
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to time and cost limitations, comprehensive molecular characterization efforts now take
advantage of high-throughput molecular profiling technologies, such as next-generation
sequencing and microarray-based measurements. These technologies allow molecular
profiling of cells for different types of alteration at multiple levels, including genome,
epigenome, transciptome and proteome.
Projects, such as The Cancer Genome Atlas (TCGA; http://cancergenome.nih.gov/),
the International Cancer Genome Consortium (https://icgc.org/), Therapeutically Ap-
plicable Research to Generate Effective Treatments (TARGET; https://ocg.cancer.gov/
programs/target), and Cancer Genome Characterization Initiative (http://ocg.cancer.gov/
programs/cgci), are all recent large-scale profiling projects that utilize recent high-
throughput molecular characterization technologies. All these projects have produced
an unprecedented amount of molecular data on tens of thousands of tumor samples
across tens of tumors types. The majority of such projects also provide clinical data
on tumor samples included in the study and therefore enable integrative computational
analyses on produced data sets. The common goal of these large-scale projects is to
provide researchers with a catalog of cancer-associated alterations in each tumor type.
Comprehensive results emerging from these studies are helping us in not only better
understanding how specific alterations might drive initiation and progression of cancer
but also identifying clinically-relevant therapeutic targets in tumor cells.
1.3 Enabling computational tools for cancer research
Molecular alterations cataloged by large-scale cancer profiling projects have helped us
better stratify tumor into genomically-defined cancer subtypes. However, we are still
challenged with utilizing all available molecular profiles and turning them into person-
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alized therapies. This is mostly due to our limited understanding of gene functions on
a systems-level, where we still cannot predict the effects of various cancer-associated
alterations on overall cellular pathways. Computational approaches, however, have the
potential to identify disregulated processes within tumor cells by leveraging integrative
approaches and analyzing the multidimensional molecular profile data. Therefore, these
tools are important in bridging the gap between unprecedented molecular data produced
by high-throughout profiling methods and the use of these datasets for developing a
better understanding of cancer biology.
The availability of extensive cancer profiling data created a need for tools that can:
(i) reduce the data into simple yet useful abstractions, such as mutation and copy-number
events; (ii) help identify altered pathways and phenotypic signatures in cancer cells;
(iii) provide utilities to access complex data sets and ease the interpretation of results by
researchers.
For example, different types of data sets available from the TCGA project have
driven the development of a variety of powerful computational tools, including
but not limited to: The Cancer Imaging Archive (http://www.cancerimagingarchive.
net/), Cancer Genome Workbench (https://cgwb.nci.nih.gov/), Integrative Genomics
Viewer (https://www.broadinstitute.org/igv/), cBioPortal for Cancer Genomics (https:
//www.cbioportal.org/), UCSC Cancer Genomics Browser (https://genome-cancer.
ucsc.edu/), Broad GDAC Firehose (http://gdac.broadinstitute.org/), MD Ander-
son GDAC MBatch (http://bioinformatics.mdanderson.org/main/TCGABatchEffects:
Overview), IntOGen (https://www.intogen.org/search), Regulome Explorer (http:
//explorer.cancerregulome.org/), The Cancer Digital Slide Archive (http://cancer.
digitalslidearchive.net/). All of these tools have proven useful for researchers without
bioinformatics expertise who find it difficult to handle the enormous data sets generated
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by large-scale projects.
1.4 Implications of computational approaches on cancer therapeu-
tics
1.4.1 Target discovery and development
Cancer genomes are inherently unstable. They often have large numbers of genetic and
epigenetic alterations, but the majority of these alterations cannot be targeted via drugs.
In particular, the RAS and TP53 genes, which are commonly altered across many tumor
types, have not been easy to target therapeutically [48].
Many collaborative and multi-institutional projects that use high-throughput ap-
proaches to discover and characterize new targets in cancer are trying to address
this problem from different angles. The Cancer Cell Line Encyclopedia (http://www.
broadinstitute.org/ccle/home), Achilles Project (http://www.broadinstitute.org/achilles),
Cancer Therapeutics Response Portal (http://www.broadinstitute.org/ctrp) and TAR-
GET are good examples to such research efforts. All these projects are similar in the
way they rely on mining large-scale genomic data, utilize systems biology approaches
for comprehensive analyses of their data sets and characterize their findings for func-
tional significance with experimental approaches. Therefore, computational approaches
that help with identification of optimal therapeutic targets from large-scale profiling data
sets play a crucial role for this kind of target discovery and development purposes.
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1.4.2 Personalized therapy
While current clinical practice tends to change only slowly, there is a major opportunity
in the development of genomically informed precision medicine, which uses genetic
and molecular profiling tailored to the individual patient to optimize treatment choice.
Computational tools have a strong promise to accelerate this development and improve
its efficiency.
Drawing on what we have learned from the cancer genomes, new kinds of cancer
clinical trials are being developed, based in part on the extraordinary treatment response
to some targeted therapies. The key aspects of these trials are (i) a specific and accurate
match between genomic alterations in patient samples and targeted therapeutics (e.g., a
PI3K inhibitor for a PI3K mutated tumor); (ii) combining several such matches under a
unified selection protocol. However, genomic information alone is often not sufficient
to accurately predict the response to treatment; therefore, one remaining challenge in
this line of therapy is data integration: to combine all types of clinical and genomic
information on patients and evaluate the efficacy of a therapy based on combined data
sets (Chapter 3).
1.4.3 Basket trials
Many new targeted clinical trials are currently enrolling patients with very specific dis-
ease criteria and/or genomic alterations. The goal of these trials is to test whether spe-
cific targeted agents have therapeutic effects in sub-populations of patients with less
common genomic alterations that are suspected to confer sensitivity to the tested drug.
However, some of these alterations are so uncommon that the number of eligible patients
becomes the limiting factor. In these cases, so-called basket trials can be created, which
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can enroll patients from different disease backgrounds and can even include several dif-
ferent therapies. Most of the genes are altered at low frequencies, but when combining
patients with multiple cancer types in a single basket trial, their sensitivity to specific
drugs can be tested (Figure 1.1).
Cancer 
Patient
Statius
Metabolic
Vulnerabilities
Computational
Screen
Genomic
Proﬁling
Xenograft &
Primary Culture
Vulnerability Testing
in vitro and in vivo 
Clinical Trials 
Figure 1.1: Computational approaches have a key role in personalized and/or
precision cancer therapy. Computational methods can identify can-
didate therapeutic vulnerabilities from the genomic profile of a re-
cently diagnosed cancer patient. These individualized vulnerabilities
can then be tested in models established from patient’s tumor sample,
such as primary cell cultures or xenografts. Once a vulnerability is
verified, “basket” clinical trials can be designed to test the efficacy of
the drug on patients who are predicted to have this particular vulnera-
bility.
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CHAPTER 2
PIHELPER: AN OPEN SOURCE FRAMEWORK FOR DRUG-TARGET AND
ANTIBODY-TARGET DATA
2.1 Summary
The interaction between drugs and their targets, often proteins, and between antibodies
and their targets is important for planning and analyzing investigational and therapeu-
tic interventions in many biological systems. Although drug-target and antibody-target
data sets are available in separate databases, they are not publically available in an inte-
grated bioinformatics resource. As medical therapeutics, especially in cancer, increas-
ingly uses targeted drugs and measures their effects on biomolecular profiles, there is an
unmet need for a user-friendly toolset that allows researchers to comprehensively and
conveniently access and query information about drugs, antibodies and their targets. The
PiHelper framework integrates human drug-target and antibody-target associations from
publically available resources to help meet the needs of researchers in systems pharma-
cology, perturbation biology and proteomics. PiHelper has utilities to i) import drug-
and antibody-target information; ii) search the associations either programmatically or
through a web user interface (UI); iii) visualize the data interactively in a network; iv)
export relationships for use in publications or other analysis tools. PiHelper is free soft-
ware under the GNU Lesser General Public License (LGPL) v3.0. Source code and
documentation are at http://bit.ly/pihelper. We plan to coordinate contributions from the
community by managing future releases.
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2.2 Introduction
In cancer biology, systems pharmacology and perturbation biology, researchers de-
signing targeted drug experiments often need to choose targeted drugs and antibodies
of interest for their experimental studies. For such studies, drug- and antibody-target
databases are valuable resources and are increasingly publicly available in computable
formats. Unfortunately, this information is in separate databases that use mostly incom-
patible formats, making it difficult to integrate data across different resources. This,
coupled with strict constraints on distribution of the data, hinders access to up-to-date,
integrated data.
Here we describe an open-source framework, PiHelper for easy aggregation, integra-
tion and visualization of drug- and antibody-target data from multiple sources. PiHelper
provides a platform-independent, command-line tool to help users, with minimal con-
figuration, import and export drug- and antibody-target information in a human- and
gene-centric manner; a Java application programming interface (API) and a REST-ful
(Representational State Transfer) web service to facilitate programmatic access to the
aggregated data; and a web-based UI to help users query data in a gene-centric manner
and export the results as an image or undirected, binary network.
We believe PiHelper will facilitate hypothesis generation and design of new experi-
ments by enabling researchers to access and query integrated drug-target and antibody-
target data from multiple resources in an automatic way.
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Table 2.1: Aggregated data resources: PiHelper enables integration of ten pub-
licly available drug-target and drug-antibody resources.
Data Resource Type of Data
DrugBank [52] Drug-target
Kyoto Encyclopedia of Genes and Genomes Drug [49] Drug-target
Rask-Andersen et al. [73] Drug-target
The Genomics of Drug Sensitivity in Cancer [93] Drug-target
Garnett et al.[36] Drug-target
Cancer.gov Drug-annotation
The Human Protein Atlas [88] Antibody-target
Tibes et al. [86] Antibody-target
Pawlak et al.[70] Antibody-target
Pathway Commons [19] Gene-sets
2.3 Components
2.3.1 Administration module
The administration module provides a command-line interface (CLI) for users to import
data into a database or export the aggregated data to tab-deliminated format for further
analysis. The importer component supports automatic fetching of background gene
information, gene-sets, gene-centric drug-target and antibody-target annotations from
multiple resources (Table 2.1). Importing data from these resources is accomplished
in an automatic manner through PiHelper’s admin CLI. The admin module contains
specific data converters for each resource and frees the user from handling different file
formats and merging data across resources. The user also has the option to import drug-
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and antibody-target data from custom, tab-delimited files.
Once the database is populated through the admin tool, the exporter component can
be utilized to export all drug and antibody data to a tab-delimited text format (TSV).
These files can then be used for further analysis tools; e.g., by importing the data into
Cytoscape as a binary network and running graph-based queries or visualizing larger
networks [78].
2.3.2 Web-based user interface
The web-based UI distributed as part of PiHelper enables users to query antibodies and
drugs in a gene-centric manner [72]. It also helps visualize the resuls as a binary net-
work and export the final network in either Scalable Vector Graphics (SVG), Portable
Network Graphics (PNG), GRAPHML or Simple Interaction (SIF) Formats. The vi-
sualization of the query results as an interactive network is accomplished through the
Cytoscape Web library [60]. The Web UI features automatic validation of the gene
names, preloaded gene-sets representing most of the well-known canonical pathways in
the query page; details for a gene, drug, antibody or the targeting interaction upon click-
ing on the corresponding element within the network, options to expand the network
based on either genes or drugs in the network, and to download the network for external
use (see Figure 2.1).
2.3.3 Core module
The core module provides the model Java classes and basic finder methods. The model
classes consist of basic elements, such as Drug, Gene and DrugTarget, that capture
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Figure 2.1: PiHelper supports visualization of gene centric drug- and
antibody-target relations as networks for easier investigation. The
web user interface allows querying available drug- and antibody-target
relations by gene symbols (e.g. EGFR and ERBB2). The result-
ing network allows interactive investigation of targeted drugs (orange
hexagons), antibodies (blue triangles) and their target products (nodes
with gene symbol labels). PiHelper also allows exporting the interac-
tions (edges) to various formats, e.g. SVG (Scalable Vector Graphics)
and SIF (Simple Interaction Format).
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drug- and antibody-gene relationships. These elements, together with their querying
methods, help developers build custom applications or analysis tools that depend on
drug or antibody annotation data. Beside the Java API, the core module also includes
a web service component that provides basic querying methods through REST proto-
cols. The web service supports obtaining the results either in JavaScript Object Notation
(JSON) and HyperText Markup Language (HTML). The former provides flexibility for
developers who prefer other programming languages than Java; and the latter enables
users to interact with the database via their web-browser of choice.
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CHAPTER 3
INTEGRATION OF COMPUTATIONAL TOOLS TO FACILITATE CANCER
RESEARCH
3.1 Summary
High-throughput profiling methods can facilitate data-driven discoveries, but it can only
does so with the help of computational tools. Computational tools allow researchers to
test different theories from the data in an efficient manner, hence help reduce the turnover
time of the analyses. These tools, however, are often specialized to address different
parts of the problem; therefore, scientific studies are driven by so-called pipelines, where
multiple tools are combined in an integrative and sequential way to analyze, normalize
and process the data step by step to get to a scientific question.
Integrated computational pipelines or tools have the ability to provide additional an-
notations on biological entities, hence making it easier to interpret and prioritize results
that are clinically relevant in cancer research. For example, pathway and drug-target
data sets, when combined with genomic alteration data, can help with clinically relevant
uses of all these data sets. Another example to such applications is the use of down-
and upstream relationships between genes to suggest drugs of possible interest that can
indirectly target a particular genomic alteration event in cancer samples. Furthermore,
aggregating data sets of different types and creating links between them for better inte-
gration will allow us build better visualization tools that can guide oncologists in their
decision making in treating patients.
In this chapter, we provide examples to such integrated computational tools that were
developed as part of this dissertation to help cancer researchers in their studies.
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3.2 Adding drug-target annotations into cBioPortal for Cancer Ge-
nomics
The cBioPortal is a web-based, free resource that helps researchers explore, visualize
and analyze multidimensional cancer genomics data [34, 17]. To make molecular profil-
ing data more accessible, the portal reduces the complex profiling data sets into different
types of alteration events: genetic, gene expression, proteomic and epigenetic. The tool
allows researchers to easily create interactive plots that summarize the data across tumor
studies, samples, genes and pathways. The portal also supports higher-level analyses on
gene-level data, including but not limited to pathway and survival analyses. All com-
bined, the portal is a tool that reduces the barrier between the cancer genomics data and
researchers that do not have the bioinformatics expertise to address data integration and
analysis challenges posed by large data sets.
Targeted-drug therapies, in which a specific molecular target within a cellular mech-
anism is blocked by a small molecule, hold substantial promises for therapies, especially
cancer. In this sense, the interaction between drugs and their targets, often proteins, is
important for planning and analyzing therapeutic interventions in many biological sys-
tems. To this end, we added support in cBioPortal for gene-centric drug-target informa-
tion from a diverse set of data resources, with the help of PiHelper (Chapter 2). There
are currently two points of entries to the drug-target information on cBioPortal: network
analysis and patient view.
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Figure 3.1: Inclusion of targeted-drug information in gene networks can help
identify therapeutic strategies based on the genomic profiles.
Genes such as TP53, MYC and PLEC (nodes in the network) are
highly altered (shades of red) in TCGA ovarian cancer, but cannot
be targeted for thereaputic purposes. EGFR and ERBB2, although
not frequently altered in this cohort of samples, are in the neighbor-
hood of these genes and these entities can be targeted by the use of
FDA-approved selective drugs (orange hexagons connected to genes
via edges). Gene networks (genes as nodes and curated pairwise inter-
actions between genes as edges) help identify such possible therapeu-
tic intervention opportunities for this type of a cohort-based analysis.
3.2.1 Extending gene network view with drug-target information
The network tab in cBioPortal provides interactive analysis and visualization of net-
works altered in the cancer study of interest. The interactions between pairs of genes
are acquired from Pathway Commons repository and by default, the network of inter-
est provides information on the neighborhood of all query genes with multidimensional
genomic data (the frequency of alteration by mutation, copy number alteration and op-
tionally mRNA up- and down-regulation) overlaid onto each of the network participants.
We extended this functionality to also show drugs that can be used to target genes in the
current network view (Figure 3.1). This new feature allows users to display U.S. Food
and Drug Administration approved drugs, cancer drugs defined by NCI Cancer Drugs,
or all drugs targeting the query genes.
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Figure 3.2: Visualization of linked data provides clues about potential per-
sonalized therapy opportunities. When a patient has a targetable
genomic alteration, such as an amplification of the Androgen Recep-
tor (AR), clinical trials that are of interest in the context of this ge-
nomic alteration, targeting agent and disease can be listed with details
on how these pieces of information are associated with each other (red
arrows connecting drug names, clinical trials and drug information) to
help guide clinical decisions.
3.2.2 Matching patients to drug treatments and clinical trials
Beside the summary statistics across patients within a cohort, cBioPortal also allows
summaries and visualization on a single tumor. This feature, called patient view, con-
tains details on mutated, amplified, and deleted genes in a particular tumor. We have
extended this functionality to help match individual patients to effective treatments and
clinical trials. Using the drug-target data imported from PiHelper, the portal lists drugs
that target the altered genes in a given sample and provide a list of relevant clinical tri-
als (Figure 3.2). These clinical trials are filtered based on the tumor type that matches
with the sample’s classification and drugs that are of interest in the given genomic back-
ground.
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3.3 Automated extraction of prior information from signaling
databases
3.3.1 Inferring quantitative network models from profiling data
Biological pathways are valuable resources for a wide spectrum of computational meth-
ods in system biology, ranging from analysis of high-throughput profiles to simulation.
The major advantage of using network models is to have an implicit definition of inter-
nal network dynamics and the structure of the connectivity. This approach also enables
conducting in silico experiments and predicting the behavior of the system under dif-
ferent conditions or upon perturbation. These types of networks can be inferred from
different types of cellular profiles for modeling purposes and this approach has provided
great insight into the behavior biological systems [62, 30, 94].
The high-throughput assays provide several advantages over conventional tech-
niques, especially in comprehensive experimental setups, by enabling rapid data produc-
tion in relatively high resolution. Moreover, application of these new high-throughput
technologies provide better quantitative cell biology models through high coverage of
molecular species. One such high-throughput technology in the proteomics field is
reverse-phase protein assays (RPPA), an assay method that provides high-precision and
reproducible measurements of protein expression levels [87, 86]. Each run of RPPA in-
volves micro-scale printing of cell lysates onto chips and then detection of protein levels
in each printed lysate by application of selected antibodies; and a single run can produce
1000 times more data points using considerably less sample volume compared to con-
ventional laboratory techniques such as western blots [80]. These properties of RPPA
and its similar technologies facilitate the validation and application of protein-network
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based modeling studies [70].
BP-guided network inference algorithm takes proteomic data as input, calculates the
marginal probability distributions of each possible interaction through Belief Propaga-
tion algorithm and generates distinct network model solutions by sampling from this
probability distribution (Figure 3.3) [67]. The application of this BP-guided network
modeling framework on high-throughput proteomic measurements of melanoma and
sarcoma cells upon single- and double-drug perturbation experiments revealed accurate
network models that can predict effective treatment strategies [54, 66].
3.3.2 Improving model inference with the help of prior information
Use of prior information can tremendously increase low signal-to-noise level in complex
systems such as large signaling network models. This becomes especially important for
network model inference methods where the number of system parameters and possible
interactions between entities grow exponentially as the networks get larger – therefore
making network inference unfeasible for various cases. Large data produced from high-
throughput proteomics experiments when complemented with the prior information on
biological pathways provides myriad opportunities for network model inference meth-
ods; but only few of these methods leverage prior information in an effective way [43].
3.3.3 PERA: Prior Extraction and Reduction Algorithm
We developed a software tool, PERA, to automatically extract prior information from
multiple signaling databases in the BioPAX format and generate a prior information net-
work. PERA takes a list of phospho-proteins identified by their HGNC symbols (e.g.
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Figure 3.3: Belief Propogation (BP) guided network inference enables pro-
ducing predictive quantitative network models from experimen-
tal data. In a typical perturbation biology experiment, protein level
readouts can be obtained from single/double drug perturbation exper-
iments and changes in the levels of these proteins can then be fed into
the BP-guided network inference algorithm for inferring quantitative
network models. These models can later be used to run in silico per-
turbation experiments and identify effective therapeutic strategies.
AKT1), phosphorylation sites (e.g. pS473) and their molecular status (i.e., activating or
inhibitory phosphorylation, total concentration) as input and then finds directed signal-
ing paths between these entities. These paths are then reduced to directed interactions
between signaling molecules represented in a Simple Interaction Format (SIF). Within
the PERA framework, the prior information is extracted from components of the Path-
way Commons 2 database in four steps (Figure 3.4):
1. Using the paths-between graph query algorithm [31], PERA generates a sub-graph
of Pathway Commons, which contains all the input proteins, all known connec-
tions between these proteins and their first neighborhoods.
2. Using the phosphorylation and activity state information, input entities are
mapped to the corresponding protein states in the graph-of-interest. During this
mapping step, protein states that do not match with either the corresponding an-
notation for phosphorylation or activity state are filtered out. Phosphorylation site
mismatches up to 6 residues are tolerated during the filtering step to account for
phosphorylation site ambiguities due to either database curation errors or cross-
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Figure 3.4: Prior Extraction and Reduction Algorithm (PERA) can summa-
rize curated detailed pathways as simple interactions between
protein entities to improve the predictive power of BP-guided net-
work inference. The overall PERA procedure consists of four basic
steps: 1) getting the network that maximally connects the biologi-
cal entities that are annotated at least with one gene; 2) fine mapping
of nodes to the entities by considering the phosphorylation and state
information; 3) Finding the minimum distance between two sets of
mapped entities; 4) Producing a simple interaction network represent-
ing the prior information that can be used as an input to the BP-guided
network inference.
organism annotations.
3. Paths that result in the addition or subtraction of a profiled phosphorylation are
extracted and mapped to phospho-protein nodes. For total protein nodes all non-
phospho-protein specific directed signaling paths are included.
4. The results are converted into Simple Interaction Format (SIF) for compatibility
with other network tools.
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PERA can be applied to any pathway database that exports to BioPAX and can be
configured for searching paths of arbitrary length. The PERA software is available at
http://bit.ly/bp prior as free software under LGPL 3.0. We have recently extended our
BP-guided network inference algorithm to work with prior network information and
have shown that use of prior information considerably improved the predictive power of
the network models of BRAF-resistant melanoma cell lines [54].
3.4 Integration of cancer genomics and pathway analysis tools to
better understand functions of genes
A biomolecular network, often called a pathway, is an abstraction that biologists have
found extremely useful in their efforts to describe and understand the inner workings of
the cell. A pathway is a set of interactions, or functional relationships, between the phys-
ical or genetic components of the cell, which operate in concert to carry out a biological
process. Detailed and comprehensive pathway information is the foundation for under-
standing disease mechanism and will enable genomic medicine to move from a mostly
correlative science (e.g., disease gene association by GWAS) to one that considers the
cause of the disease (i.e., non-functional pathway).
In the light of this, cancer is now being considered as a disease of pathways instead
of genes and their alterations alone. This suggests that investigating mutations in genes
in a pathway-centric way should enable a better understanding of altered mechanisms
(e.g. apoptosis) in cancer. This kind of data integration, where information about altered
genes are represented as a property of the participants in a pathway diagram, can be
accomplished with pathway visualization of different granularity: simple interaction
networks or detailed process diagrams.
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3.4.1 Pathway Commons: a single point of access to biological path-
way information
Within the last three years the number of publicly available pathway databases have in-
creased from 123 to more than 300 [9], making more and more pathway information
computationally accessible for various use cases. Although the pathway data is frag-
mented and presented in different formats across different data sources, various path-
way aggregation services combine and normalize pathway data across a number of data
sources for further applications. Pathway Commons is one such service that acts as a
common point of access to biological pathway information collected from public path-
way databases [19]. It runs cPath software to collect rich pathway information from
various sources, such as Reactome and NCI-Nature Pathway Interaction Database, in
BioPAX format and integrates them at the entity level by matching identical elements
based on their external references [18, 47, 76].
Furthermore, Pathway Commons uses numerous publicly available data sources that
provide detailed information on other types of biologically important molecules – e.g.
DrugBank, CheBI and PubChem [90, 26, 89, 13, 71]. The Pathway Commons data
import pipeline normalizes the pathway data coming from different resources against
these biological knowledge bases and therefore eases mapping external data resources
on biological entities that are represented in different pathways.
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3.4.2 Using cancer genomics data in gene-centric, simple network
diagrams
PCViz is a web-based, interactive network visualization tool that enables quick explo-
ration of genes with respect to their interacting partners. PCViz takes a set of gene names
as input, uses Pathway Commons web services to obtain a network in Simple Interac-
tion Format (SIF), provides basic network complexity management (e.g. showing fewer
nodes) and supports iterative expanding of the network of interest by adding/removing
genes from the view. By default, the tool does not provide any disease-related informa-
tion for the networks shown to the researcher.
To provide easier access to cancer genomics data within simple network views,
where nodes represent human genes and edges represent interactions between these
genes, we added support to PCViz for obtaining information on cancer-related alter-
ations. This feature allows researcher to load a network of interest and then overlay
gene-centric alteration data from one or more cancer studies onto the network compo-
nents. The alteration data for a given network is obtained using cBioPortal’s web service
and once loaded, different shades of color red on genes show the alteration frequencies
(Figure 3.5) We furthermore extended our complexity management tool in PCViz to take
alteration frequencies into account when filtering. When a researcher starts pruning a
network on PCViz to make the network smaller and manageable, we prioritize keeping
genes that are altered at high frequencies and that are the closest to the user’s genes of
interest in the network over the others.
We believe this feature will allow users to discover genes that play an important role
in cancer or help expand the list of their genes of interest based on the combination
of pathway- and genomics-level annotations. The PCViz software is available at http:
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//github.com/PathwayCommons/pcviz/ as free software under LGPL 3.0.
3.4.3 Overlaying cancer genomics data onto detailed pathway dia-
grams
Chisio BioPAX Editor (ChiBE) is a free, open-source network visualization and edit-
ing tool for biological pathway models. ChiBE helps querying and analyzing pathway
data represented by the BioPAX format and creates process-centric visualizations using
SBGN Process Description Language. The tool is integrated with Pathway Commons
database and therefore allows easy acquisition of curated pathway data from multiple
resources. Given a set of genes of interest, it supports searching the Pathway Commons
database via paths-between, neighborhood or common up- and down-stream queries.
We structured the latest version of ChiBE (v2.0) as a genomics-oriented pathway ex-
ploration tool that facilitates pathway analyses within genomics contexts for researchers
working in genomics field. ChiBE allows easy access to high-throughput cancer ge-
nomics data, thanks to its integration with cBioPortal. This feature enables users to do
automated mapping of cancer-related associations onto pathways for streamlined anal-
ysis. Similar to cBioPortal, ChiBE lets researchers access data from multiple cancer
studies (mostly from TCGA) and restrict the analysis to a set of cases or set of data types
(including gene expression changes, mutation and copy-number alterations). Once the
genomic alteration data sets are loaded for a given pathway, gene alteration frequen-
cies across the user-provided patient cohort are color coded on the biological entities
in the pathway (Figure 3.6). Integration of ChiBE with cBioPortal provides a power-
ful analysis and visualization work-flow that opens up new opportunities for genomics
researchers [6].
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(a)
(b)
Figure 3.5: Information about alteration frequencies in specific genes can be
overlaid on gene networks to identify important members of the
pathways in cancer. Biological networks (e.g. the neighborhood of
MDM2) can help getting an overview of functionally related genes
(nodes) and their interactions (edges) from curated pathway databases.
a) Simple interaction network for MDM2; b) Network view where
cancer-related alteration frequencies in the cohort of samples from
TCGA Glioblastoma study are overlaid on the genes (shades of red).
Although the query gene MDM2 is altered at relatively low frequen-
cies, its interaction partner, CDKN2A, is altered at high frequencies in
this cancer study, providing insight about functional interplay between
these two genes in the glioblastoma context.
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Figure 3.6: Integration of detailed pathway diagrams and cancer genomics
data enables better investigation of cancer biology and functional
relevance of specific gene alterations in cancer. A) A component of
PI3K pathway shown in CHiBE with sample cancer genomics data
overlaid onto nodes (darker shades of gray: higher alteration fre-
quency in TCGA Breast Cancer study). B) Gene-level alteration sum-
mary from cBioPortal for the same set of genes in A, but without
pathway information. C) Same pathway in A, but the overlaid data is
only restricted to a different type of data set (gene expression). Figure
is adapted from Babur et al., 2014 [6].
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CHAPTER 4
PREDICTION OF INDIVIDUALIZED THERAPEUTIC VULNERABILITIES
IN CANCER FROM GENOMIC PROFILES
4.1 Summary
Somatic homozygous deletions of chromosomal regions in cancer, while not necessarily
oncogenic, may lead to therapeutic vulnerabilities specific to cancer cells compared
to normal cells. A recently reported example is the loss of one of two isoenzymes
in glioblastoma cancer cells such that use of a specific inhibitor selectively inhibited
growth of the cancer cells, which had become fully dependent on the second isoenzyme.
We have now made use of the unprecedented conjunction of large scale cancer genomics
profiling of tumor samples in The Cancer Genome Atlas, and of tumor-derived cell
lines in the Cancer Cell Line Encyclopedia, as well as the availability of integrated
pathway information systems, such as Pathway Commons, to systematically search for
a comprehensive set of such epistatic vulnerabilities.
Based on homozygous deletions affecting metabolic enzymes in 16 TCGA cancer
studies and 972 cancer cell lines, we identified 4104 candidate metabolic vulnerabilities
present in 1019 tumor samples and 482 cell lines. Up to 44% of these vulnerabilities
can be targeted with at least one FDA-approved drug. We suggest focused experiments
to test these vulnerabilities and clinical trials based on personalized genomic profiles
of those that pass pre-clinical filters. We conclude that genomic profiling will in the
future provide a promising basis for network pharmacology of epistatic vulnerabilities
as a promising therapeutic strategy.
Supplementary web site is available at http://bit.ly/project-statius.
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4.2 Introduction
Comprehensive cancer profiling studies, such as The Cancer Genome Atlas (TCGA)
and other studies by the International Cancer Genome Consortium, have helped identify
many genomic alterations in cancer genomes, including homozygous deletions that of-
ten result from genomic instability. Deletions that confer a proliferative advantage, such
as the homozygous deletion of a tumor-suppressor gene, are selected in cancer cells via
clonal expansion [40]. Other deletions with relatively little effect on the tumor’s prolif-
erative capabilities can be seen at low frequencies when they are, by chance, co-selected
with other oncogenic events. Both types of deletions, however, result in the loss of a lo-
cus that often contains multiple genes. Such a deletion may not be lethal to a cell if one
or more unaffected partner genes (e.g., an isoenzyme) can sufficiently carry the load of
the deleted partner, but the loss of these passenger genes may create therapeutic vulner-
abilities (see Figure 4.1). Upon loss of an initial gene, interference with the function of
its partner gene(s) may result in cell death, a phenomenon known as synthetic lethality.
Muller et al. [68] recently published a case study for synthetic lethality for glioblas-
toma. Enolase performs an essential function in cells, catalyzing the conversion of 2-
phosphoglycerate and phosphoenolpyruvate in the glycolytic pathway. At least three
known genes encode enolase isoenzymes: ENO1, ENO2, and ENO3. ENO1 has been
shown to be homozygously deleted in certain glioblastomas, probably as a passenger
event to the deletion of ERFFI1, but the tumor cells are able to survive due to the ac-
tivity of other enolase encoding genes, in particular ENO2. Although the loss of ENO1
alone may not be lethal, cancer cells lacking ENO1 are selectively vulnerable to the
loss of ENO2 (i.e., synthetic lethality), whereas non-cancer cells with intact ENO1 can
tolerate a loss of ENO2.
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Figure 4.1: Deletions, often, result in the loss of a locus (blue bars) that often
contains multiple genes. These deletions can sometimes cause loss
of a metabolic gene as a passenger event. These types of alterations
are not lethal to a cell if another gene can sufficiently carry the load of
the deleted metabolic gene, but the loss of these passenger genes may
create therapeutic vulnerabilities in tumors.
Most of the cancer genomics research focuses on identifying driver alterations by
frequency or occurrence pattern and exploiting them to treat cancer [50, 65, 83, 21].
However, there is an opportunity to exploit synthetic lethalities specific to particular
populations of cancer cells created by the homozygous loss of genes responsible for
core cellular functions. These are rare, patient-specific events and there are no existing
tools for identifying these vulnerabilities for a given patient. A system that can effi-
ciently analyze genomic data from biological samples to identify particular therapeu-
tic vulnerabilities in cancer cells specific to those samples based on potential synthetic
lethal partner genes can identify personalized treatments to inhibit or kill those cancer
cells.
Here, we describe a computational method, Statius1, to systematically predict
1named after the Roman poet, Publius Papinius Statius, who is known for his famous poems Achilleid
and Thebaid.
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metabolic vulnerabilities in tumor samples from genomic profiles. We present results
obtained from the analysis of sixteen publicly available cancer studies (Figure 4.2). In-
tegrating data, in an automated manner, from multiple data resources–including several
pathway databases, drug-target annotation resources and cancer genomics utilities– we
were able to predict sample-specific metabolic vulnerabilities, which result from a ho-
mozygous deletion event in the corresponding sample, and list drugs that can help ex-
ploit each particular vulnerability. The complete list of the predicted vulnerabilities can
be found at http://cbio.mskcc.org/cancergenomics/statius.
Statius
Genomic	Pro�ilesfrom	Tumor	Samples
Metabolic	Pathways
Targeted	Drugs MetabolicVulnerabilities Test	inCell	LinesComputationalScreen
Figure 4.2: Integration of cancer genomics, metabolic pathway and targeted
drugs data allow identification of personalized therapeutic vulner-
abilities in cancer. Statius imports cancer genomics data provided
by the cBioPortal [17, 35], along with pathway and drug annotations
from a customizable list of external resources. It then produces a list
of sample-specific vulnerabilities categorized by the cancer study as
output. These potential vulnerabilities can be further tested in cell
lines bearing the vulnerability of interest.
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4.3 Results
4.3.1 Data collection
Drug-target relationships
As a first step in our analysis, we collected information on available targeted drugs and
their known targets. For this, we gathered drug-target data from multiple curated data
resources including but not limited to DrugBank [52] and KEGG Drug [49] using the
PiHelper tool [3]. We further collected information from the National Cancer Insti-
tutes’ Online Cancer Resource (http://cancer.gov) to annotate whether a drug has been
approved for cancer therapy. We were able to extract information for 7817 targeted
drugs and 17981 drug-target relationships corresponding to these drugs. To remove
non-specific drugs we excluded from our initial analysis drugs that have more than five
known targets, leaving a total of 7625 drugs and 15210 drug targets covering 1674 genes.
Gene sets representing isoenzymes
We next created a list of all known metabolic isoenzymes as representatives of synthetic
lethal gene groups. To accomplish this, we used curated human metabolic pathway
information from Pathway Commons in BioPAX format [19, 28]. We specifically col-
lected metabolism pathways provided by Reactome and HumanCyc databases [24, 75].
Using these data resources, we extracted official gene symbols from protein entities that
catalyze the same metabolic reaction and considered them as isoenzymes.
In addition to these pathway databases, we also used metabolic enzyme information
provided by the KEGG Enzyme database [49]. For each enzyme, identified by a spe-
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cific Enzyme Commission (EC) number, we extracted the corresponding human gene
symbols and grouped them as isoenzyme gene sets.
Combining data from these three resources, we were able to extract 1290 unique
gene sets. We filtered out 1063 gene sets consisting of more than five genes, as our
preliminary screen showed that gene sets with more than five genes do not increase
the number of predicted vulnerabilities in a considerable manner, as well as those that
consist of only non-targetable genes.
Cancer studies and genomic profiles
Next, we obtained genomic profiles, minimally somatic copy-number alteration data,
from publicly available cancer studies. To obtain information on multiple studies, we
utilized the web service of the cBioPortal for Cancer Genomics [17, 35]. We used
categorical copy-number alteration (CNA) information in order to identify whether a
gene is homozygously deleted for a given sample. Whenever available, we also collected
normalized gene-expression levels for a homozygously-deleted gene of interest to see
if the gene is under-expressed compared to the rest of the samples in the same cancer
study. For this analysis, we used genomic profiles for a total of 5971 samples (4999
tumor samples and 972 cell lines) from 16 different cancer studies that had publicly
available CNA data (see Table 4.1). All but two studies we included in our set had also
the mRNA expression data available.
Additional gene annotations
Most of the isoenzymes show tissue-specific expression patterns where the expression
of an isoenzyme is restricted a single or multiple tissues. We wanted to use this context-
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specific background information in our analysis and take the tissue associated with a
cancer study, when trying to find vulnerabilities. It is also known that some genes are
essential for the viability of a cell, therefore targeting such a gene causes some level of
toxicity to all cells in an nonselective manner, making these genes unpreferred targets
for an ideal therapy.
Therefore, we annotated the genes to recognize tissue-specific expression patterns
and also essentiality. Using Tissue-specific Gene Expression and Regulation (TiGER)
database, we first extracted tissue-specific genes. We also, when possible, annotated the
cancer studies with a tissue in accordance with the TiGER terminology [59]. This data
allowed us to query for a given sample, associated with a cancer study thus a tissue,
whether a gene of interest is expected to be expressed. We next used data provided by
Database of Essential Genes (DEG) to annotate whether a gene of interest is essential
for the organism [95]. Using this data set, we mark a human gene as essential if its
homologue in any of the well-known model organisms is known to be essential for the
viability of that particular organism.
4.3.2 Identification of vulnerabilities
Sample-specific vulnerabilities
Putting all these information together, we then analyzed each sample in our data set–in
the context of the cancer study it belongs to–to identify potential metabolic vulnerabil-
ities. To accomplish this, for a given cancer study, a tumor or cell-line sample and an
isoenzyme gene set, we looked for cases where:
(i) one or more isoenzymes are lost due to homozygous deletion;
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(ii) and the other expressed isoenzymes can be selectively targeted by at least one drug.
Once we found the vulnerabilities in this selective manner, we also included all possible
drugs, selective or not, in our final results.
Vulnerability scores
To sort all predicted vulnerabilities based on their internal consistency and annotations,
we assigned a score over 4.0 to each sample-specific vulnerability. For this, we checked
whether a given sample-specific vulnerability satisfied any of the following criteria:
(i) the homozygously deleted gene is also under-expressed (or not expressed);
(ii) there are any FDA-approved drugs in the suggested drug list;
(iii) there any “cancer” drugs in the suggested drug list, where a cancer drug means a
drug that is currently FDA-approved and being used in cancer treatment;
(iv) the target of the suggested drug is not an essential gene in any of the model organ-
isms.
Vulnerabilities in tumor samples and matching cell lines
We ran our analysis on 5971 cancer samples covering 16 distinct cancer studies and
identified a total of 4104 metabolic vulnerabilities in 1019 tumor samples and 482 can-
cer cell lines (Figure 4.3(a)-(b)). 146 out of 4104 ( 4%) vulnerabilities had a score of
3; 31% 2; 51% 1; and 14% 0. Overall, we were able to identify 263 distinct homozy-
gous deletions that cause a predicted vulnerability (Table 4.2; Supplementary Data for
complete results); and we found that 220 out of 263 homozygous deletions were present
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in tumor samples and 71% of these had at least one matching cell line (Figure 4.3(c)).
We also found that 1833 (44%) of the vulnerabilities can potentially be targeted with
at least one FDA-approved drug, but in a less selective manner (Figure 4.3(d)). One
such example to this less-selective targeting is the potential use of methotrexate when
either DHFR or DHFRL1 is deleted in the sample, although the drug targets both genes
in this isoenzyme pair (Table 4.3). Furthermore, we found that 1695 out of 4104 (41%)
vulnerabilities that we identified, intervention with drugs will involve targeting at least
one essential enzyme (see Figure 4.5).
To allow better investigation of these vulnerability results, we developed a web user
interface accessible at http://cbio.mskcc.org/cancergenomics/statius. The interface al-
lows browse vulnerabilities either through a cancer study or gene set based views and
for each predicted vulnerability it provides additional context annotations and informa-
tion with external links (Figure 4.4).
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Table 4.1: We screened a total of 5971 samples from 16 different cancer stud-
ies. The majority of the cancer studies were from TCGA and the oth-
ers from different individual institutions. We annotated each cancer
study with its tissue of origin in accordance with the TiGER database
[59]. TCGA: The Cancer Genome Atlas; MSKCC: Memorial Sloan-
Kettering Cancer Center; Broad: Broad Institute; CNA: DNA Copy
Number Alteration; Exp: mRNA Expression; -: Tissue annotation not
available.
Genomic profiles
Cancer study Source Samples CNA Exp. Tissue
AML TCGA [16] 191 + + Bone marrow
ACC MSKCC [42] 60 + - -
BLCA MSKCC [45] 97 + + Bladder
BRCA TCGA [53] 913 + + -
CCLE Novartis/Broad [10] 972 + + -
COADREAD TCGA [69] 575 + + Colon
GBM TCGA [14] 497 + + Brain
HNSC TCGA 306 + + -
KIRC TCGA [23] 436 + + -
LUAD Broad [44] 182 + - Lung
LUAD TCGA 230 + + Lung
LUSC TCGA [39] 197 + + Lung
OVCA TCGA [15] 569 + + Ovary
PRAD MSKCC [84] 194 + + Prostate
SARC MSKCC/Broad [11] 207 + + Soft tissue
UCEC TCGA [48] 363 + + Uterus
Total 5971
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Table 4.2: The five most common candidate therapeutic vulnerabilities de-
tected in the analysis of 5971 cancer samples from 16 different
studies. Our analysis revealed a total of 263 candidate vulnerabili-
ties. Each of these vulnerabilities is associated with a gene set that
represents isoenzymes that catalyze a metabolic reaction and deletion
of one or more partner genes results in a vulnerability if there are tar-
geted drug(s) that can selectively inhibit the other enzymes in the gene
set. The majority of the vulnerabilities in tumors were also present in
at least one cell line.
Vulnerable samples
# Isoenzyme set Deleted gene Tumors Cell lines Metabolic reaction Drugs
1 EXTL2, EXTL3 EXTL3 173 47
glucuronyl-galactosyl-proteoglycan
4-alpha-N-acetylglucosaminyltransferase
Uridine-Diphosphate-
N-Acetylglucosamine
2 PAPSS1, PAPSS2 PAPSS2 97 17 adenylyl-sulfate kinase Adenosine-5’-Phosphosulfate
3
CPT1C, CPT1B,
CPT2, CPT1A
CPT1B 90 10 carnitine O-palmitoyltransferase L-Carnitine
4 A2M, BMP1 BMP1 68 2 HDL-mediated lipid transport Becaplermin
5
GOT1, GOT2,
GOT1L1
GOT1L1 65 27 aspartate degradation II
Maleic acid,
4’-Deoxy-4’-Acetylyamino-
Pyridoxal-5’-Phosphate
37
4.4 Methods
4.4.1 Obtaining information on isoenzymes
From pathway resources: Reactome and HumanCyc
We obtained biological pathway information from both Reactome and HumanCyc
[24, 75]. We used entity-level normalized BioPAX Level 3 outputs for both data re-
sources. The normalization was accomplished through Pathway Commons 2 and cPath
2 software to standardize external references of entities in these pathway data sets ([18];
https://code.google.com/p/pathway-commons/). We then parsed these BioPAX Level 3
pathway data using Paxtools library and extracted isoenzyme gene sets using the fol-
lowing procedure ([28, 27]; http://biopax.org/paxtools.php): We first iterated over all
BiochemicalReactions that have at least one Controller to it. For a given Biochemical-
Reaction, we then iterated over all Controller entities of the reaction and obtained corre-
sponding Xref s (external references). Using Xref s that map an entity to HGNC (HUGO
Gene Nomenclature Committee), we collect HGNC gene symbols of corresponding
controllers and treat them as isoenzyme groups. For each isoenzyme group, we keep the
name of the reaction, the pathway it belongs to and an image of the corresponding re-
action associated with that particular group for later visualization features. All reaction
images were generated with ChiBE [7]. For the described procedure, we used the whole
HumanCyc data set, but for Reactome, we only used the reactions that belong to the
Metabolism pathway (RDF ID: http://www.reactome.org/biopax/48887Pathway991).
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From KEGG Enzyme
We also extracted metabolic isoenzyme information from KEGG Enzyme database us-
ing the provider’s REST-based web service. For this, we first obtained all metabolic
enzymes, identified by their corresponding EC numbers, registered in KEGG Enzyme
(http://rest.kegg.jp/list/ec). Then, for each enzyme, we obtained all human genes that
are associated with the enzyme and created groups of isoenzymes using their gene sym-
bols. For later reference, we keep the primary name of the enzyme and the text-based
description of the reaction associated with the corresponding isoenzyme group.
Combining isoenzyme data form multiple resources and filtering
After collecting isoenzyme groups, we pooled isoenzyme groups from these multiple
resources. For isoenzyme gene sets that came from different resources but had the exact
gene composition, we used the following priority for the data resources to decide which
copy to keep in the final analysis:
(i) KEGG Enzyme;
(ii) Reactome [24];
(iii) HumanCyc [75].
4.4.2 Collecting drug-target data
To collect drug-target data from multiple resources, we used PiHelper and aggregated
data from all data resource it supports by default:
39
(i) DrugBank [52];
(ii) KEGG Drug [49];
(iii) Rask-Andersen et al., 2011 [73];
(iv) Genomics of Drug Sensitivity in Cancer [93];
(v) Garnett et al., 2012 [36];
(vi) Cancer.gov (http://cancer.gov).
We ran PiHelper with the default parameters and exported all aggregated drug-target
data in TSV (tab-separated values) format as previously described ([3]). This provided
us with a list of genes that can be targeted with a drug and we used this information to
annotate all genes in our isoenzyme gene sets.
4.4.3 Labeling genes using additional annotations
Annotating tissue-specific expression patterns
For tissue-specific gene expression annotation, we used data produced by Tissue-specific
Gene Expression and Regulation, TiGER [59]. We downloaded raw file containing
tissue-specific UniGene lists and mapped this information, i.e. whether the expression
of a gene is restricted to a single tissue, using gene symbol to UniGene maps from the
same provider. We also adopted the tissue terminology used by TiGER and annotated
cancer studies we used in our study in accordance with this terminology (Table 4.1).
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Annotating essential genes
To annotate genes that are known to be essential in a model organism, we utilized data
provided by Database of Essential Genes, DEG [95]. For this, we downloaded the whole
database and used gene symbol based annotations for only eukaryotes. We annotate all
human genes in the database as essential in our analysis. For non-human essential genes,
we used homology-group data sets provided by the HomoloGene (http://www.ncbi.nlm.
nih.gov/homologene) to map these genes to their human homologues. When annotating
a gene as essential, we always include the species information as part of the annotation
for future reference. We collected annotations from the following model organisms:
(i) Homo sapiens;
(ii) Mus musculus;
(iii) Drosophila melanogaster;
(iv) Saccharomyces cerevisiae;
(v) Caenorhabditis elegans;
(vi) Danio rerio;
(vii) Arabidopsis thaliana.
4.4.4 Handling cancer studies and genomic profiles
We accessed public data for cancer studies listed in Table 4.1 using cBioPortal’s web
service ([17, 35]; http://cbioportal.org). For each study:
(i) we first collected all case IDs;
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(ii) we then obtained categorized, gene-centric CNA data (when possible, we used data
generated through either GISTIC or RAE algorithms: -2: Homozygous deletion;
-1: Heterozygous deletion; 0: Diploid; 1: Gain; 2: Amplification) [65, 83];
(iii) when available, we used normalized Z-scores for gene-centric mRNA expression
and treated values smaller than -2 as under-expressed for a particular sample;
(iv) manually assigned tissues based on the type of the cancer.
One exception to these general rules was the Cancer Cell Line Encyclopedia, where
normalized mRNA expression data was missing. For this study, we used median-
normalized gene-centric probe levels and treated log2 values smaller than 5, which cor-
responds to upper limit of the lower quartile of all expression data, as under-expressed.
A list of genomic profile IDs that were utilized for this analysis can be found within
the supplementary information. Further details for each genomic profile can be accessed
from the cBioPortal web site: http://cbioportal.org.
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(a) Number of vulnerabilities for each study
(b) Proportion of vulnerable cell
lines and tumors
Cell LineTumors
15664 43
Testable
(c) Homozygous
deletions that result in
a vulnerability
Experimental drug FDA-approved drug Cancer drug
≈ 41 therapeutic vulnerabilities
(d) Proportion of vulnerabilities
that can be targeted with either an
FDA-approved or a cancer drug
Figure 4.3: Systematic screen of cancer samples revealed metabolic vulnera-
bilities that are of therapeutic interest in a uniform way across
different cancer types. (a) Across 16 cancer studies, we identified a
total of 4101 vulnerabilities. (b) We screened 5971 samples (972 cell
lines and 4999 tumor samples) and found 1019 tumor samples and
482 cancer cell lines to have possible metabolic vulnerabilities (red).
(c) All vulnerabilities were attributable to 263 distinct homozygous
deletion events; 156 (60%) of these deletions were shared between
at least one cell line and one tumor sample. (d) 44% of all identi-
fied vulnerabilities can potentially be targeted with an FDA-approved
drug (green) and furthermore 8% with an FDA-approved drug that is
currently known to be used in cancer therapy (orange).
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(a) (b)
Figure 4.4: Four vulnerabilities, with different contexts, identified in Ovarian
Serous Cystadenocarcinoma (TCGA) cancer study. Each vulner-
ability is associated with a sample and a metabolic context. Further-
more, for each vulnerability, the gene sets are annotated to provide
information whether a gene is homozygously deleted (red; HomDel),
essential (black; E/G), not expressed (orange; N/E), show tissue spe-
cific expression (green; TS/E) or is known to be selectively targeted
by a drug (gray; Drugs: N). For gene sets extracted from Pathway
Commons, the metabolic reaction of interest is visualized as an image
that was produced by ChiBE [7].
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Table 4.3: Vulnerabilities that can potentially be exploited with a cancer drug
– a drug that is approved by FDA for use in cancer therapy. In some
cases, deletion of either of partner genes can result in a therapeutic
vulnerability. For example, TOP2A and TOP2B are isoenzymes that
function as ATP-hydrolysing DNA topoisomerases. Out of 5971 cases
(tumor or cell line samples), 70 of them have either TOP2B- or TOP2A-
deletion (*). Either of these deletions create vulnerabilities that can be
exploited with drugs, such Doxorubicin or Etoposide, that selectively
inhibit these isoenzymes.
# Isoenzyme set Cases Metabolic reaction Drug(s) of interest
1 TOP2B*, TOP2A* 70 DNA topoisomerase (ATP-hydrolysing)
Daunorubicin, Epirubicin, Doxorubicin,
Etoposide, Dexrazoxane
2 DHFR*, DHFRL1* 68 dihydrofolate reductase Methotrexate, Pemetrexed, Pralatrexate
3 IKBKE*, TBK1*, IKBKB, CHUK* 46 IkappaB kinase Arsenic trioxide
4 LIG1, LIG3, LIG4* 43 DNA ligase (ATP) Bleomycin
5 P4HB*, MTTP* 34 Chylomicron-mediated lipid transport
Vandetanib, Nilotinib, Imatinib,
Bosutinib, Dasatinib
6 RRM1*, RRM2* 33
Synthesis and interconversion of
nucleotide di- and triphosphates
Clofarabine, Fludarabine, Gemcitabine
7 CMPK1, CMPK2* 20 UMP/CMP kinase Gemcitabine
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4.5 Discussion
Cancer cell contain many somatic genomic alterations, some of which may result in
therapeutic vulnerabilities. Therapeutic approaches targeting such vulnerabilities are
promising, because they are expected to be lethal to cancer cells but not to healthy (e.g.,
non-cancer) cells, thus reducing the potential for toxic side-effects. Here we present
a systematic approach to identify a subset of such vulnerabilities, involving metabolic
pathways, by taking advantage of publicly available data resources. As a proof of con-
cept, we ran our analysis on 16 cancer studies available via the cBioPortal for Cancer
Genomics and predicted a total of 4104 metabolic vulnerabilities. We included the Can-
cer Cell Line Encyclopedia (CCLE) in our analysis as a separate cancer study and this
allowed us to match vulnerabilities in tumor samples with those in cell lines. Overall,
we found 2706 vulnerabilities resulting from 220 distinct homozygous deletion events
in 1019 tumor samples. 71% of these vulnerability-causing homozygous deletions were
also present in at least one cell line, therefore opening the possibility of testing a ma-
jority of these predicted vulnerabilities in vitro. Reassuringly, using this systematic
method, we were able to detect a previously verified metabolic vulnerability, which is
due to a homozygous deletion affecting an enolase isoenzyme [68]. Unlike other stud-
ies that have previously predicted metabolic vulnerabilities using a theoretical model of
cancer metabolism, here we interpreted all data sets in a sample-specific manner [32].
This helped us capture many vulnerabilities that were not reported previously (Table
4.2) [68, 32].
Furthermore, we based our analysis on homozygous deletions in cancer samples
with a particular focus on metabolic pathways, but our method can easily be extended
to signaling pathways and also to any disabling genomic or epigenomic event, such as
mutations and hyper-methylation events. We restricted our analysis to consider only ho-
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mozygous deletions, because at the time of the study, the number of samples that have
a copy-number profile was considerably higher compared to the number of samples that
have either mutation or methylation profile. Moreover, we only used metabolic path-
ways, because details of metabolic reactions are provided at a better level of granularity
in many of the pathway data resources. This allowed us to infer potentially synthetic
lethal gene sets from the pathway resources with higher confidence. For many signaling
pathways, this type of inference is considerably harder to accomplish, since they are not
as well-characterized and well-curated as metabolic pathways yet.
The quality of our vulnerability predictions highly depends on the quality of the ho-
mozygous deletion calls made for each metabolic gene. A false-positive homozygous
deletion call, for example, will also lead to a false-positive vulnerability prediction in our
analysis. To overcome this problem, we assign a higher a score to vulnerabilities when
the homozygously deleted gene is also under-expressed in a specific sample. Another
likely source of false-positive predictions is our assumption that all metabolic reactions
are essential for cell viability, therefore genes catalyzing the same reaction form a syn-
thetic lethal group. These types of issues, however, can be easily addressed by testing
a predicted vulnerability in vitro using one of the cell lines that has the vulnerability of
interest.
To better prioritize the vulnerabilities in terms of their applicability to the clinic and
their reliability, we assigned a score (over 4.0) to each individual vulnerability we iden-
tified based on the following criteria. First, to emphasize the likelihood of homozygous
deletion being true, we checked whether transcripts of homozygously deleted genes are
also expressed relatively at low levels compared to the diploid samples. Next, we looked
if the suggested drug to exploit a vulnerability is either FDA-approved or already being
used in cancer therapy, where satisfying either criteria indicates not only better availabil-
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ity of the drug for validation experiments but also relatively easier translation to clinical
trials. Finally, we checked whether targeting the vulnerability will inhibit an essential
gene, hence increasing the possibility of a toxic effect for the host.
These criteria reflect a subjective view of a reliable vulnerability prediction, and can
be expanded by incorporating more annotation and supportive data sets to the analysis.
For example, various drug screen studies and shRNA knock-down assays provide rela-
tive sensitivities of cell lines towards inhibition of various cellular species as public data
sets [20, 10]; and this information can be further utilized in the context of vulnerabili-
ties, where sensitivities that can be explained by a predicted vulnerability are given an
extra score. Another possible extension to our scoring scheme is to give extra scores to
vulnerabilities for which suggested drugs are currently being tested in clinical trials for
the tumor type that matches the patient’s.
Our analysis identifies only vulnerabilities for which the target gene can selectively
be inhibited by a compound, but for each vulnerability prediction we also report drugs
that are less selective yet still potentially interesting for exploiting a vulnerability. Con-
sidering both selective and non-selective drugs, our results show that 44% of the identi-
fied vulnerabilities can potentially be targeted with an FDA-approved drug; moreover, a
smaller fraction, 8%, of all vulnerabilities seem to be targetable with drugs that are both
FDA-approved and already being used in cancer therapy (Table 4.3).
Opportunities to exploit these vulnerabilities have previously been overlooked; be-
cause, genomic alterations that cause such vulnerabilities are relatively less frequent
within each cancer study. We show that with the help of a systematic method that can
efficiently combine data from diverse resources, it is possible to identify vulnerabilities
that cover a considerable number of patients when aggregated across different cancer
studies. We believe this type of systematic and patient-specific treatment suggestion
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will prove essential especially in designing “basket trials” that will investigate the ef-
fects of a targeted agent against a specific genetic alteration (see Figure 1.1).
59%
41%
Cell Lines
(2709 vulnerabilities)
58%
42%
Tumor Samples
(1395 vulnerabilities)
Essential Nonessential
Figure 4.5: 1695 out of 4104 (41%) predicted metabolic vulnerabilities, inter-
vention with drugs will involve targeting at least one essential en-
zyme. These vulnerabilities correspond to 41% of the vulnerabilities
in cell lines and 42% in tumor samples.
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CHAPTER 5
CANCER-ASSOCIATED RECURRENT MUTATIONS IN RNASE III
DOMAINS OF DICER1
5.1 Summary
Mutations in the RNase IIIb domain of DICER1 are known to disrupt processing of 5p-
strand pre-miRNAs and these mutations have previously been associated with cancer.
Using data from the Cancer Genome Atlas project, we show that these mutations are re-
current across four cancer types and that a previously uncharacterized recurrent mutation
in the adjacent RNase IIIa domain also disrupts 5p-strand miRNA processing. Analysis
of the downstream effects of the resulting imbalance 5p/3p shows a statistically signifi-
cant effect on the expression of mRNAs targeted by major conserved miRNA families.
In summary, these mutations in DICER1 lead to an imbalance in miRNA strands, which
has an effect on mRNA transcript levels that appear to contribute to the oncogenesis.
5.2 Introduction
MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate expression
of their transcript targets [12] DICER1 is a key enzyme that is responsible for cutting
the 5p and 3p strands of the pre-miRNA in the early stages of the miRNA biogenesis.
Processing of the 5p and 3p strands, which is carried out by the RNase III domains of
DICER1, is necessary for loading the functional miRNA strand into the RISC complex.
Previous studies have identified recurrent mutations in the RNase IIIb domain in differ-
ent cancer types [33, 41, 91, 92, 77, 4, 51, 25]. These mutations (at residiues E1813,
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D1810, D1709, E1705 and R1703) were shown to be in the active site of the enzyme and
were proven to disrupt the processing of the 5p stand of the miRNA [82]. Others have
shown that hotspot mutations in the RNase IIIb domain cause depletion of 5p strands
relative to their corresponding 3p strands, leading to an asymmetry in the abundance of
the two [38, 4].
Although the asymmetry in the miRNA processing due to hotspot mutations has
been characterized using model organisms; the effect of this miRNA depletion on the
mRNA levels have not been studied extensively in the context of the human tumors. It
is, for example, unknown whether it is the 5p-strand depletion or increased 3p-strand
accessibility that promotes the cancer. In either of the cases, it is also unknown whether
there is any particular miRNA or miRNA family of which depletion or over-expression
drives this phenotype. In this study, using human tumor data from the Cancer Genome
Atlas (TCGA) project, we wanted to better characterize the effects of DICER1 mutations
on miRNA and mRNA profiles of the patients.
5.3 Results
5.3.1 Hotspot mutations in RNase IIIb domain disrupt 5p strand
miRNAs
We first asked whether we could observe the asymmetry in the miRNA processing us-
ing the miRNA-Seq data. For this, we looked whether any of the previously identified
hotspot mutations were present in the TCGA data set (14 cancer types, 5535 sequenced
samples). We found that 15 out of 123 DICER1 mutants carried a mutation in the RNase
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IIIb domain of the protein at a previously identified hotspot (Figure 5.1a). After filter-
ing out cases that were hyper-mutated and samples that did not have miRNA-Seq data
available, we were left with 8 DICER1 hotspot mutants. We then compared the miRNA
levels in these hotspot mutants to the miRNA levels in 3171 DICER1 wildtype tumors
across multiple cancers. Confirming the results of the previous studies, we saw 5p strand
miRNAs were relatively down-regulated in mutants and the changes in the expression
of 5p strands were significantly different than the 3p strands (Wilcoxon rank sum test;
p < 10−29; Figure 5.1b-c).
5.3.2 A recurrent mutation in the RNase IIIa domain is associated
with 5p depletion phenotype
Having observed a phenotype characterized by relative 5p strand depletion in hotspot
RNase IIIb mutants, we asked whether any of the other DICER1 mutants had a similar
phenotype. To investigate this, we first estimated the abundance of 5p strands relative to
3p strands for each patient: mi5,3 = log2(m
i
5/m
i
3), where m
i
x is the median expression of
the x-strand miRNAs in patient i. As expected, the majority of the hotspot mutants had
exceptionally low 5p-strand abundance compared to DICER1 wildtypes (Figure 5.1d).
In addition to the known hotspots mutants, we identified three more DICER1 mutant
cases that had relatively low 5p abundance (mi5,3 < 0). One of these three DICER1
mutants had a hotspot mutation in its RNase IIIb domain, but was excluded from the
initial analysis because it was a in hyper-mutated sample (Table 5.3). Surprisingly, the
other two cases with low 5p abundance had an S1344L mutation in the RNase IIIa
domain that is responsible for processing the 3p strand of the miRNA.
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5.3.3 Evolutionary analysis identifies coupling between residiues
across RNase IIIa and IIIb domains
As the observation of recurrent mutations in cancer samples is consistent with a selec-
tive functional impact of the mutation, the question arises as to the effect of the S1344L
mutations on the catalytic function of the RNase domains. Inspection of the 3D struc-
ture (or model) of the individual domain reveals that residue S1344L (in domain IIIa)
and its homologous residue T1733 (in domain IIIb) are far from the active site residues
(19.60±2.62Å distance) in their respective domains (Figure 5.1e). However, evolution-
ary couplings [63] between S1344L/T1733 and the active site residues, as deduced from
co-evolution patterns in the multiple sequence alignment of RNase III-like domains, are
fairly strong. The contradiction is resolved by inspection of the model of the RNase
IIIa - IIIb heterodimer (as inferred from the crystal structure of the RNase IIIb homod-
imer) [82]. In the heterodimer, S1344L in domain IIIa is close (11.72±1.98Å distance)
to active site of domain IIIb (residues E1813, D1810, D1709, E1705 and R1703) and
T1733 in domain IIIb is close to the active site residues of domain IIIa. These residue
arrangements and functional couplings are beautifully consistent with the observation
that mutations in S1344L in domain IIIa affect 5p processing, as observed in our analy-
sis of the effect of these mutations on the balance of 3p/5p miRNA expression profiles
in cancer samples. This is consistent with the earlier observations that mutations in the
active site residues of domain IIIa affect 3p processing, while mutations in the active
site residues of domain IIIb affect 5p processing. The subtly of the difference between
the earlier and current observation lies in the residue interactions across the heterodimer
interface [85] and in fact the earlier observation of 3p/5p asymmetry are confirmed here
by completely independent observation in human cancer samples.
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5.3.4 DICER1 mutations are biallelic in samples with 5p strand
miRNA depletion phenotype
Other studies have shown that DICER1 hotspot mutations are biallelic in cancer, where
a disabling mutation acts as the second hit to the enzyme [92, 77, 51] Based on this
observation, the relative 5p depletion phenotype of RNase III mutants in our analysis
suggested that these patients also had a second event disabling the other DICER1 allele.
To address this question, we re-analyzed the sequencing data available for DICER1
mutant cases, this time using a different pipeline that can better identify insertions or
deletions. In a majority of the DICER1 RNase III hotspot mutant samples, we were able
to identify a secondary disabling genomic event affecting the other DICER1 allele (Table
5.4). Furthermore, we found that these biallelic mutated cases had lower 5p abundance
than the other DICER1 mutants in our earlier analysis.
5.3.5 Hotspot mutations lead to up regulation of 5p-miRNA target
gene sets
Having identified possibly functional mutations in DICER1 and their effect on the
miRNA profiles, we tested whether these mutations lead to functional changes in the
mRNA profiles. Others have previously characterized DICER1 hotspot mutations using
mouse-derived cell lines as in vitro models [4, 51, 38] These studies have shown that
the mRNA profiles of cell lines with different DICER1 RNase IIIb hotspot mutations
had different mRNA signatures compared to the DICER1-wildtype cell lines. They fur-
ther found an association between the down-regulated miRNAs and their differentially-
expressed target transcripts, which suggests a differential regulation of the mRNA levels
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due to asymmetric miRNA processing in DICER1 hotspot mutants.
Although there is in vitro evidence that the asymmetry in the miRNA processing
lead to significant changes in the mRNA profiles; there are no previous reports that
describe the differential mRNA expression in accordance with the miRNA expression
data from human tumors. To this end, we identified 12 cases across four cancer types
that both had RNA-Seq data available and carried a hotspot RNase III mutation either
in the IIIa or IIIb domains of the DICER1 protein. We then wanted to check whether
we could identify a common mRNA expression signature for these DICER1 RNase III
hotspot mutants in comparison to 1212 DICER1 wildtype cases in those four cancer
studies. For this, we decided to restrict our analysis to the Uterine Corpus Endometrial
Carcinoma (UCEC) study where the RNA-Seq data set contained 8 DICER1 RNase
III mutants and 222 DICER1 wildtypes. We found 10 genes to be significantly up-
regulated and none to be down-regulated in the hotspot mutated cases when compared to
wildtypes (p < 0.05 after Bonferroni correction; Table 5.5). Notably, we found higher
expression of HMGA2, a well-known oncogene and target of let-7 miRNA family, in
mutants [56, 64, 12].
Following up on this, we asked whether the up-regulated genes in mutants were tar-
gets of particular miRNA families. To answer this question, we conducted a gene set
enrichment analysis (GSEA) using well-known biological pathways and well-conserved
miRNA family target genes as our query gene sets [81]. Our analysis showed strong en-
richment of both let-7/98/4458/4500 and miR-17/17-5p/20ab/20b-5p/93/106ab/427/518a-
3p/519d target genes in RNase III mutants (Table 5.1; FDR ¡ %10). For both families,
5p strand of the miRNA is the predominant strand and as expected, in RNase III mutant
cases, 5p-strand miRNAs that belong to these families were relatively down-regulated.
Results from the GSEA also suggested that there was relatively weaker enrichment for
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other miRNA families and NOTCH-related pathways (Table 5.1; FDR ¡ %15). A ma-
jority of the enriched gene sets (5 out of 7) represented miRNA family targets, which
suggests the gene expression signature associated with these RNase III hotspot mutants
is more likely to be mediated by depleted miRNA families rather than a common bio-
logical pathway. In accordance with the 5p strand depletion phenotype, a majority of
these miRNA families (3 out of 5) were 5p-strand dominated. For the other two fami-
lies, miR-29abcd and miR-101/101ab, although 3p is the pre-dominant miRNA strand,
we saw that members of these families were down-regulated as a family in DICER1
mutants compared to wildtype, which might be due to an indirect regulatory effect of 5p
miRNA depletion.
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Figure 5.1: Disabling mutations in RNase III domains of DICER1 lead to 5p
miRNA depletion in cancer. a) A majority of the hotspot mutations
in the RNase III domains of the DICER1 are present in the Cancer
Genome Atlas project across multiple cancer types. b-c) Hotspot mu-
tations in the RNase IIIb domain cause relative down-regulation of
5p-stand and up-regulation of 3p strand miRNAs in mutants compared
to DICER1 wild-types. d) Hotspot mutated samples tend to have rel-
atively lower 5p miRNA abundance compared to DICER1 wild-type
cases. Using sample-specific relative 5p abundances, we identified
three more DICER1 mutated cases that also show 5p-depletion phe-
notype (m5,3 < 0). e Two out of three cases, who has relatively low
5p abundance, had a S1344 mutation in the RNase IIIa domain that is
responsible for processing the 3p strand of the miRNA. The mutated
amino acid, S1344 in RNase IIIa domain, is homologous to T1733
in RNase IIIb domain, which in turn is evolutionary coupled to the
hotspot mutations. This indicates that S1344, although it is in RNase
IIIa domain, is important for proper functioning of the RNase IIIb do-
main.
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Table 5.1: Gene sets representing targets of conserved miRNA families are
up-regulated in DICER1 RNase III mutants compared to wild-
types. To see the effect of relative depletion of 5p miRNAs on
the mRNA profiles, we conducted a Gene Set Enrichment Analysis
(GSEA) on mRNA profiles of Uterine Corpus Endometrial Cancer
(UCEC) samples. We showed that targets of the major miRNA fam-
ilies, which are predominantly 5p-originating, are differentially up-
regulated in DICER1 mutants compared to wild-types. For each of
these miRNA families, we saw consistent down-regulation of 5p strand
(green) and up-regulation of 3p strand (red) miRNA members. mut:
DICER1 hotspot mutant; wt: DICER1 wildtype; Diff. Exp.: Differ-
ential expression (log2 ratio of mRNA/miRNA levels); p value: The
probability for the null hypothesis that the genes in the set are not differ-
entially up-regulated in mutants compared to wildtypes; FDR: p value
corrected for multiple hypothesis testing.
miRNA set
miRNA target set
(# of genes)
p value FDR
Diff. Exp. of mRNAs
(8 mut.s vs 222 wt.s)
Diff. Exp. of miRNAs
(5 mut.s vs 107 wt.s)
let-7/98/4458/4500 90 0.0001 0.08 | ||| || || |||| || ||| | ||| |||
miR-17/17-5p/20ab/20b-5p/93/-
106ab/427/518a-3p/519d
42 0.0002 0.08 ||| || ||| | ||| |
miR-29abcd 87 0.001 0.11 | ||| || ||||| || | || || |||
miR-101/101ab 26 0.001 0.11 || ||| ||| ||
miR-15abc/16/16abc/195/-
322/424/497/1907
51 0.001 0.11 | ||| ||| | | ||| | || | | | || |||
All 16358 -4 -2 +20 +4
|| || | || || || | |||||| |||| || || ||||| ||| || ||||| | || | ||||
-4 -2 0 +2 +4
|||| || ||| |||| || ||||| ||| | ||
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5.4 Methods
The code for analyses conducted in this study and supplemental results for each of the
analyses are available at http://bit.ly/dicer5p. In this study, we used miRNA, RNA-Seq
and sequencing data from 14 TCGA cancer studies (Table 5.2).
Table 5.2: We analyzed a total of 2855 samples with miRNA and sequencing
data across 14 cancer studies from the Cancer Genome Atlas.
Abbreviation Cancer study name # of samples
BLCA Bladder urothelial carcinoma 137
BRCA Breast invasive carcinoma 190
COADREAD Colorectal adenocarcinoma 241
GBM Glioblastoma multiforme 248
HNSC Head and Neck squamous cell carcinoma 267
KICH Kidney chromophobe 64
KIRC Kidney renal clear cell carcinoma 184
LGG Brain lower grade glioma 286
LUAD Lung adenocarcinoma 180
LUSC Lung squamous cell carcinoma 51
PRAD Prostate adenocarcinoma 248
STAD Stomach adenocarcinoma 244
THCA Thyroid carcinoma 399
UCEC Uterine corpus endometrial carcinoma 116
Total 2855
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5.4.1 Identification of DICER1 hotspot mutations
We first asked whether previously identified DICER1 hotspot mutations at residues
E1813, D1810, D1709, E1705 and R1703 are present in TCGA data sets. For this, we
conducted a cross-cancer query on cBioPortal (http://cbioportal.org) [35] and found 123
out of 5535 sequenced samples to be DICER1 mutated (Figure 5.1a and File all tcga-
dicer1-2014 03 20.maf ). Of these 123, 12 tumor samples had at least one hotspot
DICER1 mutation in the RNase IIIb domain.
5.4.2 Analysis of the miRNA-Seq data
We next wanted to see if hotpost mutant tumors had a distinct miRNA expression pro-
file compared to other samples. To address this question, we first obtained normalized
miRNA-Seq data sets (Level 4) from the most recent TCGA analysis runs (January
15, 2014) as generated with the Firehose analysis pipeline (http://gdac.broadinstitute.
org/runs/analyses 2014 01 15/). miRNA-Seq data for Glioblastoma Multiforme can-
cer study was not available from this resource, therefore, for GBM, TCGA Level 1
microarray expression data were processed and normalized using the AgiMicroRna R
package and using settings further explained in a previous study [46, 61].
We then wanted to see whether particular miRNAs were differentially expressed
in DICER1 RNase IIIb mutants compared to DICER1 wild-type cases. We initially
excluded hotspot mutants from the analysis if they were either categorized as hyper- or
ultra-mutated, or if the predicted effect of the mutation was not high as assigned by the
Mutation Assesor (Table 5.3) [74]. To check for differential expression, we compared
distribution of each miRNA expression in mutants versus wildtypes by using a Wilcoxon
rank sum test. We adjusted the p-values using a Bonferroni correction for multiple
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hypothesis testing. To estimate the change in expression, we calculated the difference
in median log2-based expression values between mutant and wildtype samples (Figure
5.1b-c).
Table 5.3: To identify the miRNA expression signature associated with
hotspotDICER1mutations, we excluded hyper-mutated cases from
the initial analysis. Ultra- or hyper-mutated cases tend to have higher
number of somatic mutations compared to other samples. To identify
miRNA profiles associated with the hotspot DICER1 mutants in a re-
strict way, we first conducted the differential miRNA expression anal-
ysis only on samples with relatively low number of somatic mutations
(n < 1000).
Sample identification Reason for exclusion
TCGA-A6-6141 Hyper-mutated sample
TCGA-AP-A0LM Low allele frequency and ultra-mutated sample
TCGA-BS-A0UV Low FIS and ultra-mutated sample
TCGA-CG-5733 Low FIS and hyper-mutated sample
TCGA-D1-A17Q Ultra-mutated sample
To check whether the distribution of differential miRNA expression was different for
different strands of the miRNA, we conducted pairwise comparisons of the differential
expression values for different strands of miRNA: 5p, 3p and N/A where N/A means
no strand information was available for that miRNA. For this comparison, we utilized
Wilcoxon rank sum test and adjusted the p-values using a Bonferroni correction.
5.4.3 Additional mutation calling for DICER1 hotspot mutants
Having observed different levels of respective 5p strand depletion in hotspot DICER1
mutants, we wanted to see if patients with extreme phenotypes had any additional
germline or somatic mutations affecting the other DICER1 allele. We, therefore, down-
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loaded whole-exome binary sequence alignment and mapping (BAM) files for normal
and tumor samples corresponding to the hotspot DICER1 mutated cases from CGHub
https://cghub.ucsc.edu/. We then used HaplotypeCaller utility from the Genome Anal-
ysis Toolkit to do the joint variant calling on these BAM files [29]. To annotate
the variants, we used Mutation Assesor and Oncotator (http://www.broadinstitute.org/
oncotator/) tools [74].
We next used the annotated mutation file to look for new mutations that were not
called by the TCGA pipeline (File: muts tcga-dicer1-secondcall-2014 04 09.maf ). In
addition to the previously called hotspot mutations, we were able to identify other dis-
abling DICER1 alterations in samples that showed relatively low 5p strand abundance
(Table 5.4).
5.4.4 Identification of evolutionary couplings in RNase III domain
In our miRNA expression analysis, in which we estimated the relative 5p strand abun-
dance for each patient, we saw that two samples that have the biallelic S1344L mu-
tation had considerably low 5p abundance. Based on the fact that RNase III dimer-
ization is necessary for proper DICER1 functioning, we wanted to see how S1344L
could affect 5p miRNA processing [85]. For this we ran evolutionary couplings
(ECs) analysis with default settings on the EVFold server (v1.11) [63]. We provided
DICER HUMAN (UniProt:Q9UPY3, http://www.uniprot.org/uniprot/Q9UPY3) as the
input protein, residues 1423-1922 of DICER1 as the sequence of interest to center the
RNase IIIb domain and PDB:2eb1 (http://www.rcsb.org/pdb/explore.do?structureId=
2eb1) as the reference structure [82]. We set the e-value for jackhmmer as 10−10 and
the inference method for determining the evolutionary couplings as Pseudo Likehood
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Maximization (PLM).
The analysis showed that the most strongly constrained residues (with strong
couplings to other residues) were 1708, 1709, 1813, 1705 and 1704. The contact
maps were fairly structured, indicating they were of reasonable quality (File: EvCou-
plings DICER1 RNaseIIIb with 2eb1.zip). Well-known active site residues with rela-
tively high EC strength included 1709, 1813 and 1705. We found that residues 1709,
1813 and 1705 were coupled to 1733. These ECs, however, were not consistent with
the known structural constraints as 1709, 1813 and 1705 were not in close proximity to
1733 in the 3D structure (19.60±2.62Å distance).
A multi-alignment involving both RNase IIIa and IIIb domains indicated that S1344
in RNase IIIa domain was homologous to 1733 in RNase IIIb domain. We then inspected
the corresponding locations of these residues in the 3D protein structure and found that
ECs from residues 1709, 1813 and 1705 to 1733 were better explained in the RNase
IIIb dimer context, where active site residues in one domain were closer (11.72±1.98Å
distance) to the 1733 (i.e. S1344) in the other domain. Based on these observations,
we concluded that these couplings might indicate an important role for S1344, together
with other active site residues (1709, 1813, 1705) in RNase IIIb domain, in 5p strand
processing.
5.4.5 Analysis of the RNA-Seq data
We next asked whether DICER1 hotspot mutants had distinct gene expression pro-
files compared to other samples. To answer this question, similar to miRNA data,
we obtained processed and normalized RNA-Seq data sets (Level 4) from the most
recent TCGA analysis runs (January 15, 2014) as generated with the Firehose analy-
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sis pipeline (http://gdac.broadinstitute.org/runs/analyses 2014 01 15/). We found that
THCA, GBM, COADREAD studies had RNA-Seq data for less three hotspot mutants,
hindering a statistically robust comparison. We, therefore, decided to restrict our analy-
sis to only UCEC study, where there were 8 DICER1 hotspot mutant and 222 DICER1
wildtype samples.
We then conducted a differential gene expression analysis using the limma voom
R package on the gene-level RSEM counts for UCEC study and contrasted the hotspot
mutant to wildtype samples [55]. We found 9 genes to be significantly up-regulated–and
none down-regulated–in mutants (p < 0.05 after Bonferroni correction; Table 5.5; File:
DGE-UCEC-muts vs wts-allGenes.tsv).
5.4.6 Gene set enrichment analysis (GSEA)
Having observed up-regulated genes in DICER1 hotspot cases compared to wildtypes,
we wanted to see whether these genes were targets of particular miRNAs or members of
canonical pathways. To answer this question, we utilized a gene set enrichment analysis
(GSEA) using the UCEC data set.
To create gene sets for targets of the well-conserved miRNA families, we first down-
loaded predicted miRNA targets from TargetScan (Release 6.2) and then aggregated
these predictions using miRNA family-member associations to obtain a list of targets
for each miRNA family [57]. We next filtered out predictions with conservation score
lower than 90% and then collected targets that were in the upper 5 percentile considering
their context score (i.e. scores lower than −0.3555). Using these filtered predictions, we
created gene sets that were compatible with the conventional GSEA analysis [81].
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We combined these miRNA target gene sets with gene sets representing well-known
and curated Reactome pathways from MSigDB [24, 58]. This gave us a total of 719
gene sets, consisting of 674 gene sets for pathways and 45 for targets of miRNA families
(File: GSEA-GeneSymbols-mirFamilies and Pathways.gmt). For the GSEA, we utilized
the romer utility from the limma toolkit and used the contrast model that we used in the
RNA-Seq data analysis [79]. We set the number of rotations to 10,000 and for each
gene set, tested whether the genes in the set were enriched for any direction (up- or
down-regulation).
We found genes in 7 different sets to be significantly enriched towards up-regulation
and none in the reverse direction (FDR < 0.15; Table 5.1; File: GSEA-UCEC-
muts vs wts.tsv). 5 out of 7 gene sets were representing target genes for miRNA families
and 3 of these were miRNA families for which 5p strand was the predominant strand
according to miRBase [37].
5.5 Discussion
In summary, we showed that biallelic DICER1 RNase III hotspot mutations, although
infrequent across cancers, lead to relative depletion of 5p stand of miRNAs. In addition
to known hotspot mutations, we were able to identify a previously unknown recurrent
DICER1 mutation, S1344, that also leads to the 5p depletion phenotype. In accordance
with the miRNA depletion phenotype, we saw up-regulation of genes that are well-
known targets of the 5p-dominant miRNA families in mutant samples. It still remains
unclear whether up-regulation of a particular gene, such as HMGA2, or activation of a
particular pathway, such as NOTCH, is contributing to the oncogenesis as a result of the
5p miRNA depletion in these cells.
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Table 5.4: Hotspot DICER1 mutations that lead to 5p depletion phenotype
are biallelic in TCGA samples. For the majority of the hotspot
DICER1 mutants, we were able to identify a second genomic event that
affect the other DICER1 allele. These biallelic mutated samples were
enriched for stronger 5p depletion phenotype (i.e. lower m5,3) com-
pared to monoallelic alterations. THCA: Thyroid carcinoma; UCEC:
Uterine corpus endometrial carcinoma; GBM: Glioblastoma multi-
forme; COADREAD: Colorectal adenocarcinoma; CNA: Copy number
alteration; HetLoss: Heterozygous loss; N/A: Not available.
Sample identifier Cancer study Mutation CNA m5,3
TCGA-EL-A3GO THCA D1810H, K376fs - -1.43
TCGA-D1-A15Z UCEC D1810A, L539fs - -1.08
TCGA-EL-A3D5 THCA E1813G, L81fs - -1.05
TCGA-DI-A0WH UCEC
D1709N, M1821I,
K1486fs
- -1.02
TCGA-06-2569 GBM
E1705Q,
CLPSIL1053del
Gain -0.93
TCGA-A5-A0GN UCEC S1344L HetLoss -0.92
TCGA-14-0871 GBM Homozygous E1813G - -0.83
TCGA-A6-6652 COADREAD D1810N HetLoss -0.71
TCGA-B5-A11U UCEC S1344L, P1377fs - -0.63
TCGA-D1-A17Q UCEC E1705K, H341P - -0.36
TCGA-AP-A0LM UCEC
E1705A, R490H,
F1650C
- 0.36
TCGA-DM-A28C COADREAD E1705Q - 0.48
TCGA-A5-A0GH UCEC E1813G, V1731fs - N/A
TCGA-BG-A0M6 UCEC E1813A - N/A
TCGA-D1-A0ZP UCEC R1703C - N/A
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Table 5.5: A differential gene expression analysis comparingDICER1 hotspot
mutants to wildtypes showed 9 significantly up-regulated genes in
mutants. We compared the gene expression levels in 8 DICER1 mu-
tants to the levels in 222 DICER1 wildtypes using the limma voom
toolkit. We used Bonferroni correction to adjust our p-values for
multiple hypothesis testing and found 9 genes to be differentially up-
regulated in mutants (pad j < 0.05). logFC: change in gene expression
(log based)
Gene Gene ID logFC p-value adjusted p-value
HMGA2 8091 3.708 0.0000000001 0.0000016619
IGDCC3 9543 3.648 0.0000000025 0.0000409144
ACVR2B 93 1.211 0.0000000083 0.0001365400
MMP16 4325 2.333 0.0000002521 0.0041232946
C17orf63 55731 0.782 0.0000002798 0.0045772958
ADAMTS7 11173 1.993 0.0000007622 0.0124675442
IGF2BP2 10644 3.294 0.0000015289 0.0250102395
FAM171B 165215 1.801 0.0000021387 0.0349852741
MGAT5B 146664 2.875 0.0000023541 0.0385090592
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CHAPTER 6
CONCLUSION
6.1 Summary
Making use of public knowledge bases and cancer genomics data, we showed that:
(i) random passenger genomic events can create patient-specific therapeutic vulnera-
bilities that can be exploited by targeted drugs [2];
(ii) comprehensive analysis of cancer genomics data sets can reveal interesting biolog-
ical insights about specific alteration events [1].
Moreover, we explained some of the computational tools that let other researchers
better investigate cancer genomics data (cBioPortal [35, 19]), integrate biological path-
way data (Pathway Commons and BioPAX [27, 5, 6]) into their analysis and query
available therapeutic targeted drugs (PiHelper [3]). Finally, we showed how we can
integrate these data sources into their own computational approaches [22, 54, 8].
6.2 Limitations
6.2.1 Incomplete and misrepresented data in curated databases
Computational tools and approaches we described in this work all rely on public biolog-
ical information provided by curated knowledge bases. In our studies, in the process of
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integrating data from multiple resources, we have not addressed possible problems that
might be associated with the use of such knowledge bases.
In particular, in the study where we predicted therapeutic vulnerabilities in cancer
from genomic profiles, we heavily utilize curated pathway databases to identify isoen-
zymes that regulate particular metabolic reactions (Chapter 4). This means that our
approach is limited to the knowledge captured by these data resources; therefore, it
might be missing some of the therapeutic vulnerabilities that exist in the cancer cells
if information on some of the reactions and their isoenzymes have not been curated in
none of the databases yet. Similarly, our method is susceptible to misrepresentation of
reactions due to different levels of abstraction or curator’s understanding of the biologi-
cal processes. This type of curation problem might lead to either unresolvable conflicts
across data sources about biological processes or unrealistic predictions for therapeutic
opportunities.
These curation-related problems are especially pronounced for data on signaling
pathways, as our current understanding of such pathways is still limited and the exact
mechanistic steps that lead to specific cellular responses are not fully understood yet.
To minimize the problems that might be due to incomplete and misrepresented data in
curated databases, for our work, we integrated data from multiple resources to maximize
our coverage on biological processes and only focused on metabolic reactions since
these reactions are well characterized, hence less vulnerable to curation errors.
Same curation problems might also exist in data collected by the PiHelper tool
(Chapter 2) or the miRNA-target relationships utilized in our study of hotspot muta-
tions in DICER1 (Chapter 5). Specifically, the problems in the former study might stem
from missing curated data on drugs and their targets or from false target information
on particular drug-gene pairs. These problems in drug-target relations might affect our
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therapeutic predictions, causing false positive predictions for certain drug targets.
The public knowledge bases that we utilized in this work are still active and re-
searchers maintaining these resources continue to regularly release new and improved
data sets. We expect that many of the curation-related problems that we mentioned here
are going to be resolved with future releases, enabling more robust and reliable analyses
using these data sets.
6.2.2 Intra-tumor heterogeneity and misidentified genomic events
For the genomic analyses described in Chapters 4 and 5, we took advantage of high-
level, summarized and gene-centric data produced by large-scale genomic studies such
as TCGA and CCLE. These high-level genomic alterations are extracted from raw pro-
file data sets, using automated computational pipelines that help reducing the data for
different analysis purposes such the ones described in this work. Many studies make
use of similar and shared resources to summarize their data before making it publicly
available. One advantage to this is that genomic data provided by different studies are
uniformly generated and hence are comparable across multiple resources. Additionally,
since these computational tools are being used by many researchers, they are highly op-
timized for their input parameters to reduce false positive genomic event calls from the
raw data. However, verifying all of the genomic alterations identified from large-scale
data sets is infeasible due to high cost and work-load associated with such large-scale
validation efforts. Therefore, many of the genomic alterations reported by these stud-
ies are not validated unless other researchers follow-up on specific alterations for more
in-depth characterization.
Intra-tumor heterogeneity–i.e. the fact that the cells that make up a tumor are not
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the same in terms of their genomic alterations and phenotypic properties–is another
challenge that the cancer genomics field is currently tackling with. Projects like TCGA
have strict quality controls on samples included in the study, where all the tumor samples
are required to have a high purity to ensure consistent and robust results. This type of
strict inclusion criteria is not always easy to implement for many research studies due
to relatively smaller sample sets. In cases where there is high level of heterogeneity
in tumor samples, the computational pipelines fail to capture specific events that are
restricted to certain clones or they mistakenly call the event as shared across all cells in
the tumor.
In this dissertation work, we did not address these problems that might be present in
the data sets; that is, we assumed that all genomic alterations reported by various studies
were true and all tumor samples included in our studies were pure. As such, we expect
that these assumptions might have led to certain false-positive or -negative predictions
or associations that might not be possible to identify without additional investigation
(e.g. in vitro tests) on them.
6.3 Future Directions
Drawing on what we learned from large-scale cancer profiling projects like The Cancer
Genome Atlas (TCGA), new clinical trials that recruit patients based on their genomic
profiles for specific targeted therapies are already being established; but, there are still
three major challenges in translating what we learn from these data sets into the clinic:
(i) a majority of the alterations that we see in patients are not immediately actionable;
(ii) tumor cells are heterogeneous and polyclonal, which affects how cells respond to
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particular interventions;
(iii) targeted therapies are short-lived, so resistance to such therapies eventually arise
and the tumor progresses as a result (Figure 6.1).
Figure 6.1: Emergence of resistance to targeted drugs is a major challenge
in cancer therapeutics: As our understanding of molecular mech-
anisms of carcinogenesis increases, targeted drug therapies, where a
specific molecular target that is known to play a crucial role in cellu-
lar mechanism is blocked by a small molecule, are showing substantial
promises. The emergence of resistance to targeted drugs, however, is
still a challenge to be faced in the field: in spite of high response rates
of these drugs, for most of the cases resistance emerges after a rela-
tively short period of time eventually leading to cancer relapse. The
emergence of drug resistance in relatively short times casts a shadow
on the success of such targeted-drugs. The resistance mechanisms
against a majority of targeted drugs still remains unclear; but genomic
profiling of resistant tumors and cell lines provide a way to learn more
about genomic alterations that may lead to resistance in cells.
Although these issues are highly relevant for translating our understanding of molec-
ular profiling data into insights about cancer therapies, they are out of the scope of this
work and require further investigation. To solve these problems in clinics, we still need
to have a better understanding of cancer biology with the help of data-driven discovery
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processes that make good use of emerging experimental and computational approaches.
Given the pace of the technology and the constant increase in the number of cancer pro-
filing projects, we believe that being able to address these challenges and dramatically
increasing cancer therapy are just a matter of time.
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